Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Titel:
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Auteur:
Smith, Bryan D. Kaufman, Michael D. Lu, Wei-Ping Gupta, Anu Leary, Cynthia B. Wise, Scott C. Rutkoski, Thomas J. Ahn, Yu Mi Al-Ani, Gada Bulfer, Stacie L. Caldwell, Timothy M. Chun, Lawrence Ensinger, Carol L. Hood, Molly M. McKinley, Arin Patt, William C. Ruiz-Soto, Rodrigo Su, Ying Telikepalli, Hanumaiah Town, Ajia Turner, Benjamin A. Vogeti, Lakshminarayana Vogeti, Subha Yates, Karen Janku, Filip Abdul Razak, Albiruni Ryan Rosen, Oliver Heinrich, Michael C. Flynn, Daniel L.